Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study.

Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vögeler J, Koch M, Eter N, Liakopoulos S, Schmitz-Valckenberg S, Spital G.

Clin Ophthalmol. 2019 Nov 7;13:2167-2179. doi: 10.2147/OPTH.S209253. eCollection 2019.

2.

Correction to: Visual impairment and blindness in institutionalized elderly in Germany.

Larsen PP, Thiele S, Krohne TU, Ziemssen F, Krummenauer F, Holz FG, Finger RP; OVIS-Study Group.

Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):1057. doi: 10.1007/s00417-019-04277-3.

PMID:
30838438
3.

Development and validation of a multiple-choice questionnaire-based theoretical test in direct ophthalmoscopy.

Jørgensen M, Savran MM, Christakopoulos C, Bek T, Grauslund J, Toft PB, Ziemssen F, Konge L, Sørensen TL, Subhi Y.

Acta Ophthalmol. 2019 Nov;97(7):700-706. doi: 10.1111/aos.14065. Epub 2019 Feb 28.

PMID:
30816642
4.

Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?

Menzler J, Neubauer A, Ziemssen F.

Int J Ophthalmol. 2019 Feb 18;12(2):342-345. doi: 10.18240/ijo.2019.02.24. eCollection 2019.

5.

Combined Targeted Analysis of Metabolites and Proteins in Tear Fluid With Regard to Clinical Applications.

Dammeier S, Martus P, Klose F, Seid M, Bosch D, D'Alvise J, Ziemssen F, Dimopoulos S, Ueffing M.

Transl Vis Sci Technol. 2018 Dec 6;7(6):22. doi: 10.1167/tvst.7.6.22. eCollection 2018 Nov.

6.

A view to a kill? - Ambient bacterial load of frames and lenses of spectacles and evaluation of different cleaning methods.

Fritz B, Jenner A, Wahl S, Lappe C, Zehender A, Horn C, Blessing F, Kohl M, Ziemssen F, Egert M.

PLoS One. 2018 Nov 28;13(11):e0207238. doi: 10.1371/journal.pone.0207238. eCollection 2018.

7.

Visual impairment and blindness in institutionalized elderly in Germany.

Larsen PP, Thiele S, Krohne TU, Ziemssen F, Krummenauer F, Holz FG, Finger RP; OVIS-Study Group.

Graefes Arch Clin Exp Ophthalmol. 2019 Feb;257(2):363-370. doi: 10.1007/s00417-018-4196-1. Epub 2018 Nov 27. Erratum in: Graefes Arch Clin Exp Ophthalmol. 2019 Mar 6;:.

PMID:
30483949
8.

A swarm of slippery micropropellers penetrates the vitreous body of the eye.

Wu Z, Troll J, Jeong HH, Wei Q, Stang M, Ziemssen F, Wang Z, Dong M, Schnichels S, Qiu T, Fischer P.

Sci Adv. 2018 Nov 2;4(11):eaat4388. doi: 10.1126/sciadv.aat4388. eCollection 2018 Nov.

9.

[Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)].

Brinkmann CK, Chang P, Schick T, Heimes B, Vögeler J, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S.

Ophthalmologe. 2019 Aug;116(8):753-765. doi: 10.1007/s00347-018-0805-y. German.

PMID:
30367231
10.

Predictors of response to opicinumab in acute optic neuritis.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L; RENEW Study Investigators.

Ann Clin Transl Neurol. 2018 Aug 15;5(10):1154-1162. doi: 10.1002/acn3.620. eCollection 2018 Oct.

11.

Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany.

Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, Voegeler J, Koch M, Liakopoulos S, Schmitz-Valckenberg S, Spital G; OCEAN study group.

Diabetes Ther. 2018 Dec;9(6):2271-2289. doi: 10.1007/s13300-018-0513-2. Epub 2018 Oct 4.

12.

Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential.

Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D; RENEW MF-VEP Investigators.

CNS Drugs. 2018 Dec;32(12):1159-1171. doi: 10.1007/s40263-018-0575-8.

13.

Design and Baseline Characteristics of the HELP Study: An Extended and Long-Term Observation of Pathological Myopia in Caucasians.

Melzer C, Ziemssen F, Eter N, Brinkmann C, Agostini H, Haeusser-Fruh G, Rose U, Schargus M, Lorenz K, Holz FG, Schmitz-Valckenberg S.

Ophthalmologica. 2018;240(3):167-178. doi: 10.1159/000489180. Epub 2018 Jun 15.

PMID:
29909408
14.

Influence of aflibercept on platelet activation profile.

Sobolewska B, Golenko J, Poeschel S, Grimmel C, Gatsiou A, Sopova K, Biedermann T, Schenke-Layland K, Stellos K, Ziemssen F.

Exp Eye Res. 2018 Oct;175:166-172. doi: 10.1016/j.exer.2018.06.009. Epub 2018 Jun 15.

PMID:
29908884
15.

[No increase in myopia?]

Ziemssen F.

Ophthalmologe. 2018 May;115(5):418-421. doi: 10.1007/s00347-018-0697-x. German. No abstract available.

PMID:
29651549
16.

Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.

Ziemssen F, Cruess A, Dunger-Baldauf C, Margaron P, Snow H, Strain WD.

Eur Endocrinol. 2017 Aug;13(2):91-98. doi: 10.17925/EE.2017.13.02.91. Epub 2017 Aug 22.

17.

New digital methods: remodelling the harms tangent scale setting.

Leitritz MA, Bende M, Jiang L, Prokoph J, Ziemssen F, Bartz-Schmidt KU, Bende T, Besch D.

Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):975-982. doi: 10.1007/s00417-018-3938-4. Epub 2018 Mar 1.

PMID:
29497810
18.

Slit lamps and lenses: a potential source of nosocomial infections?

Sobolewska B, Buhl M, Liese J, Ziemssen F.

Eye (Lond). 2018 Jun;32(6):1021-1027. doi: 10.1038/s41433-017-0004-0. Epub 2018 Jan 30.

19.

PROSPECTIVE RANDOMIZED TRIAL ASSESSING THE IMPACT OF FEEDBACK MECHANISMS ON PATIENT POSITIONING.

Dimopoulos S, Vivell J, Ziemssen F, Bende T, Bartz-Schmidt KU, Leitritz MA.

Retina. 2019 Apr;39(4):727-735. doi: 10.1097/IAE.0000000000002006.

PMID:
29266047
20.

Correction to: pH of anti-VEGF agents in the human vitreous: low impact of very different formulations.

Sobolewska B, Heiduschka P, Bartz-Schmidt KU, Ziemssen F.

Int J Retina Vitreous. 2017 Oct 16;3:45. doi: 10.1186/s40942-017-0097-4. eCollection 2017.

21.

Quality and learning curve of handheld versus stand-alone non-mydriatic cameras.

Gosheva M, Klameth C, Norrenberg L, Clin L, Dietter J, Haq W, Ivanov IV, Ziemssen F, Leitritz MA.

Clin Ophthalmol. 2017 Aug 31;11:1601-1606. doi: 10.2147/OPTH.S140064. eCollection 2017.

22.

[Implementation of the National Guidelines for the treatment of Diabetes mellitus type 2 in secondary diabetes centers].

Marahrens L, Röck D, Ziemssen T, Kern R, Ziemssen F, Fritsche A.

Dtsch Med Wochenschr. 2017 Sep;142(18):e131-e139. doi: 10.1055/s-0043-111388. Epub 2017 Sep 8. German.

PMID:
28902377
23.

[Healthcare Research into Anti-VEGF Therapy: Selection and Methodological Precautions].

Ziemssen F, Stahl A, Dimopoulos S.

Klin Monbl Augenheilkd. 2017 Dec;234(12):1483-1492. doi: 10.1055/s-0043-115393. Epub 2017 Aug 23. Review. German.

PMID:
28834972
24.

[Ophthalmological health care of the institutionalized elderly : The OVIS study].

Fang PP, Schnetzer A, Kupitz DG, Göbel AP, Kohnen T, Reinhard T, Lorenz B, Hoerauf H, Wagenfeld L, Auffarth G, Schaub F, Thieme H, von Livonius B, Alten F, Robering A, Brandl C, Ziemssen F, Krummenauer F, Holz FG, Finger RP.

Ophthalmologe. 2017 Sep;114(9):818-827. doi: 10.1007/s00347-017-0557-0. German.

PMID:
28831559
25.

Patients' preferences for involvement in the decision-making process for treating diabetic retinopathy.

Marahrens L, Kern R, Ziemssen T, Fritsche A, Martus P, Ziemssen F, Roeck D.

BMC Ophthalmol. 2017 Aug 9;17(1):139. doi: 10.1186/s12886-017-0526-z.

26.

Establishment of a retinal hypoxia organ culture model.

Schnichels S, Blak M, Hurst J, Dorfi T, Bartz-Schmidt KU, Ziemssen F, Spitzer MS, Schultheiss M.

Biol Open. 2017 Jul 15;6(7):1056-1064. doi: 10.1242/bio.025429.

27.

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations.

Sobolewska B, Heiduschka P, Bartz-Schmidt KU, Ziemssen F.

Int J Retina Vitreous. 2017 Jun 26;3:22. doi: 10.1186/s40942-017-0075-x. eCollection 2017. Erratum in: Int J Retina Vitreous. 2017 Oct 16;3:45.

28.

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S; RENEW Study Investigators.

Lancet Neurol. 2017 Mar;16(3):189-199. doi: 10.1016/S1474-4422(16)30377-5. Epub 2017 Feb 15.

PMID:
28229892
29.

Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.

Ziemssen F, Feltgen N, Holz FG, Guthoff R, Ringwald A, Bertelmann T, Wiedon A, Korb C; OCEAN study group.

BMC Ophthalmol. 2017 Jan 19;17(1):7. doi: 10.1186/s12886-017-0401-y.

30.

Large Gaps in Care.

Ziemssen F.

Dtsch Arztebl Int. 2016 Oct 21;113(42):720. doi: 10.3238/arztebl.2016.720a. No abstract available.

31.

Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data.

Ziemssen F, Schlottman PG, Lim JI, Agostini H, Lang GE, Bandello F.

Int J Retina Vitreous. 2016 Jul 11;2:16. eCollection 2016.

32.

[Secondary diseases in high myopia].

Ziemssen F, Lagrèze W, Voykov B.

Ophthalmologe. 2017 Jan;114(1):30-43. doi: 10.1007/s00347-016-0390-x. Review. German.

PMID:
27844100
33.

Limited Time from the Diabetes Patients' Perspective: Need for Conversation with the Eye Specialist.

Marahrens L, Ziemssen F, Fritsche A, Ziemssen T, Kern R, Martus P, Roeck D.

Ophthalmologica. 2016;236(3):154-158. Epub 2016 Oct 5.

PMID:
27701169
34.

Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.

Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wiedon A, Wilhelm H, Ziemssen F.

Health Qual Life Outcomes. 2016 Sep 20;14(1):132. doi: 10.1186/s12955-016-0536-1.

35.

[Regional Differences in the Care of Patients with Neovascular Age-Related Macular Degeneration, Based on the Non-Interventional OCEAN Study].

Ziemssen F, Hufenbach U, Wiedon A, Scheffler M, Bertelmann T.

Klin Monbl Augenheilkd. 2016 Dec;233(12):1367-1377. Epub 2016 Jul 25. German.

PMID:
27454304
36.

[National guidelines for treatment of diabetic retinopathy : Second edition of the national guidelines for treatment of diabetic retinopathy].

Ziemssen F, Lemmen K, Bertram B, Hammes HP, Agostini H.

Ophthalmologe. 2016 Jul;113(7):623-38. doi: 10.1007/s00347-016-0315-8. German.

PMID:
27352282
37.

Fluctuations of the Intraocular Pressure in One Eye Influence the Intraocular Pressure in the Fellow Eye.

Voykov B, Blumenstock G, Ziemssen F, Bartz-Schmidt KU, Schultheiss M.

Curr Eye Res. 2017 Feb;42(2):211-216. doi: 10.3109/02713683.2016.1167918. Epub 2016 Jun 17.

PMID:
27314985
38.

Morphometric Optic Nerve Head Analysis in Glaucoma Patients: A Comparison between the Simultaneous Nonmydriatic Stereoscopic Fundus Camera (Kowa Nonmyd WX3D) and the Heidelberg Scanning Laser Ophthalmoscope (HRT III).

Mariacher S, Hipp S, Wirthky R, Blumenstock G, Bartz-Schmidt KU, Ziemssen F, Schiefer U, Voykov B, Januschowski K.

J Ophthalmol. 2016;2016:4764857. doi: 10.1155/2016/4764857. Epub 2016 May 30.

39.

[Economic Short-Term Cost Model for Stereotactic Radiotherapy of Neovascular AMD].

Neubauer AS, Reznicek L, Minartz C, Ziemssen F.

Klin Monbl Augenheilkd. 2016 Aug;233(8):951-7. doi: 10.1055/s-0042-100473. Epub 2016 Apr 30. German.

PMID:
27130973
40.

Ex-vivo-examination of ultrastructural changes in organotypic retina culture using near-infrared imaging and optical coherence tomography.

Schnichels S, Dorfi T, Schultheiss M, Arango-Gonzalez B, Bartz-Schmidt KU, Januschowski K, Spitzer MS, Ziemssen F.

Exp Eye Res. 2016 Jun;147:31-36. doi: 10.1016/j.exer.2016.04.011. Epub 2016 Apr 21.

PMID:
27109031
41.

Anatomical and visual outcomes of autologous thrombocyte serum concentrate in the treatment of persistent full-thickness idiopathic macular hole after ILM peeling with brilliant blue G and membrane blue dual.

Dimopoulos S, William A, Voykov B, Ziemssen F, Bartz-Schmidt KU, Spitzer MS.

Acta Ophthalmol. 2017 Aug;95(5):e429-e430. doi: 10.1111/aos.12971. Epub 2016 Feb 19. No abstract available.

42.

Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?

Ziemssen F, Bartz-Schmidt KU, Dimopoulos S.

Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):615-6. doi: 10.1007/s00417-016-3301-6. Epub 2016 Feb 18. No abstract available.

PMID:
26887826
43.

[Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice].

Heimes B, Schick T, Brinkmann CK, Wiedon A, Haegele B, Kirchhof B, Holz FG, Pauleikhoff D, Ziemssen F, Liakopoulos S, Spital G, Schmitz-Valckenberg S.

Ophthalmologe. 2016 Jul;113(7):570-80. doi: 10.1007/s00347-016-0224-x. German.

PMID:
26868827
44.

Outcomes of Primary Transconjunctival 23-Gauge Vitrectomy in the Diagnosis and Treatment of Presumed Endogenous Fungal Endophthalmitis.

William A, Spitzer MS, Deuter C, Blumenstock G, Partsch M, Voykov B, Ziemssen F, Bartz-Schmidt KU, Doycheva D.

Ocul Immunol Inflamm. 2017 Apr;25(2):239-245. doi: 10.3109/09273948.2015.1115080. Epub 2016 Jan 30.

PMID:
26829468
45.

Pre-Analytical Parameters Affecting Vascular Endothelial Growth Factor Measurement in Plasma: Identifying Confounders.

Walz JM, Boehringer D, Deissler HL, Faerber L, Goepfert JC, Heiduschka P, Kleeberger SM, Klettner A, Krohne TU, Schneiderhan-Marra N, Ziemssen F, Stahl A.

PLoS One. 2016 Jan 5;11(1):e0145375. doi: 10.1371/journal.pone.0145375. eCollection 2016.

46.

Comment on Leese et al. Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care 2015;38:488-494.

Ziemssen F, Marahrens L, Roeck D.

Diabetes Care. 2015 Dec;38(12):e207-8. doi: 10.2337/dc15-1356. No abstract available.

PMID:
26604285
47.

Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.

Ziemssen F, Sobolewska B, Deissler H, Deissler H.

Expert Opin Drug Saf. 2016 Jan;15(1):75-87. doi: 10.1517/14740338.2016.1121232. Epub 2015 Dec 11. Review.

PMID:
26568279
48.

Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy.

Dimopoulos S, Leitritz MA, Ziemssen F, Voykov B, Bartz-Schmidt KU, Gelisken F.

Clin Ophthalmol. 2015 Aug 24;9:1537-41. doi: 10.2147/OPTH.S87919. eCollection 2015.

49.

Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile.

Sobolewska B, Grimmel C, Gatsiou A, Sopova K, Klein J, Biedermann T, Stellos K, Ziemssen F.

Ophthalmologica. 2015;234(4):195-210. doi: 10.1159/000437057. Epub 2015 Aug 21.

PMID:
26305017
50.

[Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)].

Ziemssen F, Bertelmann T, Hufenbach U, Scheffler M, Liakopoulos S, Schmitz-Valckenberg S.

Ophthalmologe. 2016 Feb;113(2):143-51. doi: 10.1007/s00347-015-0099-2. German.

PMID:
26201460

Supplemental Content

Loading ...
Support Center